ABSTRACT
The clinical development of new drugs traditionally takes place in three phases, starting with small studies that evaluate a handful of patients under carefully controlled conditions and ending with studies that enroll hundreds and sometimes even thousands of patients to develop the evidence necessary to achieve regulatory approval to market the new molecule. We start this chapter by briefly describing the three stages of clinical development and then give an example from the clinical area of oncology.
